Sign in
Taking people in United StatesPhase 1

Donor Immune Cell Infusions Collected After Exercise to Prevent Leukemia Relapse After Transplant

Tests exercise-collected donor cell infusions to prevent relapse after transplant in blood cancers.

Key facts

Who runs it
University of Arizona
Where
Tucson, United StatesSee the site
Trial code
Registry title
Prophylactic DLI-X for Leukemia Relapse After HCT
Status
Recruiting
Phase
Phase 1
People taking part
180 people, planned
Started
26 Oct 2026
Expected to end
1 Jun 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Exercise Mobilized Prophylactic DLI
  • Standard Prophylactic DLI
Record updated
29 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for patients aged 0-65 with leukemia, myelodysplastic syndrome, chronic myeloid leukemia or non-Hodgkin lymphoma. They must be about to have a stem-cell transplant from a related donor. The trial tests donor white blood cell infusions to prevent relapse.

Age
0-65 years for patients. Donors must be 12-50 years old.
Sex
All sexes can join.
Disease stage
Acute leukemia (lymphoid, myeloid or undifferentiated), myelodysplastic syndrome, chronic myeloid leukemia or non-Hodgkin lymphoma.
Earlier treatment
Patients must be having a myeloablative or reduced intensity stem-cell transplant from a matched sibling donor or a haploidentical donor.
Biomarker or test result
A related donor with at least 5/10 HLA antigens in common with the patient is needed.

Main reasons for not taking part

  • Acute graft-versus-host disease grade II-IV or moderate/severe chronic graft-versus-host disease at the time of the infusion
  • Needing immunosuppressive treatment for graft-versus-host disease
  • Serious liver, kidney, lung or heart problems, as set by the record's test limits
  • Uncontrolled or severe infection, or HIV positive
  • Positive pregnancy test

The registry criteria, word for word

Show all 27 criteriaShow less

Other criteria

  • DLI Recipient Inclusion Criteria:
  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 0-65 years
  • Diagnosis of acute leukemia (lymphoid, myeloid or undifferentiated) myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) or non-Hodgkin's lymphoma (NHL)
  • Undergoing myeloablative or reduced intensity matched sibling donor (MSD) HCT or haploidentical HCT
  • Have a locally available healthy matched or haploidentical (≥5/10 HLA antigen matched) related donor between 12 and 50 years of age, consented and able to perform the exercise sessions. (see donor inclusion criteria); DLI Donor Inclusion Criteria:
  • Provision of signed and dated informed consent form
  • Must have already met transplant donor eligibility as a matched sibling donor, or HLA-haploidentical relative of the patient, including biological parents, siblings, or children, half-siblings, cousins or aunts and uncles
  • Weight is greater than 30 kg
  • Age 12 and 50 years
  • Ability to undergo phlebotomy
  • Be able complete the fitness evaluation to determine VO2max and peak cycling power. Following successful completion of the donor fitness evaluation, the patients willing to participate in the randomized trial will be enrolled
  • Donor's recipient has met eligibility requirements and agreed to participate; DLI Recipient Exclusion Criteria:
  • Acute grade II-IV aGvHD or moderate/severe chronic GvHD at time of scheduled DLI
  • Requiring immunosuppression therapy for treatment of GvHD
  • Co-morbidities: AST/ALT greater than 5 x ULN; Bilirubin greater than 2 x ULN; Creatinine greater than 2 x ULN for age or creatinine clearance/GFR <40 ml/min/1.73m2; Pulmonary function: DLCO less than 40% of normal or O2 Sat less than 92%; Cardiac: left ventricular ejection fraction less than 35%; active infection; HIV positive; Karnofsky score (adults) less than 60% or Lansky score less than 50% (pediatrics)
  • Uncontrolled or severe bacterial, fungal or viral infection
  • Positive serum or urine pregnancy test for girls post menarche or women of childbearing age
  • Severe psychiatric illness or mental deficiency making compliance to treatment unlikely and/or and/or would preclude informed consent according to IRB requirements for the study
  • Any reason, at the investigator's discretion, that the participation of the patient in this protocol would not be in patient's best interest, or where the patient would be unable to adhere to the study requirements; DLI Donor Exclusion Criteria:
  • Unable to perform graded exercise test
  • Cardiac or pulmonary disease/condition that would restrict exercise
  • Positive anti-donor HLA antibody
  • Pregnant or lactating
  • Active infection
  • Severe psychiatric illness or mental deficiency making compliance with donation unlikely and/or would preclude informed consent according to IRB requirements for the study

Where in United States

  • The University of Arizona Cancer CenterTucson, United StatesContact: Michele Chu-PilliTaking people

About the trial

What the trial wants to find out

The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo) hematopoietic cell transplantation (HCT) in patients with hematologic malignancies.

Read full original descriptionShow less

We hypothesize that pro-DLI-X will demonstrate safety and superior efficacy by enhancing graft-versus-leukemia (GvL) effects mediated by natural killer (NK) cells, γδ T cells, and CD8+ T cells, while maintaining manageable and treatment-responsive graft-versus-host disease (GvHD).

The 2 groups in the trial

  • Prophylactic DLI-X ArmTreatment being tested

    Conduct the first-in-human, randomized clinical trial comparing prophylactic exercise mobilized donor lymphocyte infusion (pro-DLI-X) with standard (non exercise mobilized) prophylactic DLI (pro-DLI) for relapse prevention following allogeneic hematopoietic cell transplantation (alloHCT) in patients with myeloid or lymphoid malignancies. Patients on this arm will receive pro-DLI-X.

    Treatment: Exercise Mobilized Prophylactic DLI

  • Prophylactic Standard DLI ArmExisting treatment, for comparison

    Conduct the first-in-human, randomized clinical trial comparing prophylactic exercise mobilized donor lymphocyte infusion (pro-DLI-X) with standard (non exercise mobilized) prophylactic DLI (pro-DLI) for relapse prevention following allogeneic hematopoietic cell transplantation (alloHCT) in patients with myeloid or lymphoid malignancies. Patients on this arm will receive standard DLI-X.

    Treatment: Standard Prophylactic DLI

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Feasibility/Pilot First-in-human Study of Exercise-mobilized NK-enriched Donor Lymphocyte Infusions (DLI-X) to Prevent Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation
Plain-language title
Donor Immune Cell Infusions Collected After Exercise to Prevent Leukemia Relapse After TransplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
29 October 2026